Publikationen der Medizinischen Klinik I 2014

Kommentare oder Korrespondenzen

1. Finkelmeier F, Kronenberger B, Köberle V, Bojunga J, Zeuzem S, Trojan J, Piiper A, Waidmann O (2014) Commentary: vitamin D deficiency and liver cancer - cause, effect or myth? Authors' reply. ALIMENT PHARM THER, 39 (12): 1429-30

2. Wiegand J, Maasoumy B, Buggisch P, Buslau A, Schiefke I, Berg T, Wedemeyer H, Sarrazin C, Hinrichsen H (2014) Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis. ALIMENT PHARM THER, 39 (11): 1342-4

Originalarbeiten

1. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, ION-1 Investigators (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. NEW ENGL J MED, 370 (20): 1889-98

2. Akoglu B, Lafferton B, Kalb S, Yosuf SE, Herrmann E, Zeuzem S, Goßmann J, Kachel HG, Scheuermann EH, Faust D (2014) Rejection quantity in kidney transplant recipients is associated with increasing intracellular interleukin-2 in CD8+ T-cells. TRANSPL IMMUNOL, 31 (1): 17-21

3. Albert JG, Finkelmeier F, Friedrich-Rust M, Kronenberger B, Trojan J, Zeuzem S, Sarrazin C (2014) Identifying Indications for Percutaneous (PTC) vs. Endoscopic Ultrasound (EUS)- Guided "Rendezvous" Procedure in Biliary Obstruction and Incomplete Endoscopic Retrograde Cholangiography (ERC). Z GASTROENTEROL, 52 (10): 1157- 1163

4. Alao JP1, Sjölander JJ, Baar J, Özbaki-Yagan N, Kakoschky B, Sunnerhagen P. Caffeine stabilizes Cdc25 independently of Rad3 in Schizosaccharomyces pombe contributing to checkpoint override. Mol Microbiol. 2014 May;92(4):777-96

5. Albert JG, Lucas K, Filmann N, Herrmann E, Schröder O, Sarrazin C, Trojan J, Kronenberger B, Bojunga J, Zeuzem S, Friedrich-Rust M (2014) A novel, stiff-shaft, flexible-tip guidewire for cannulation of biliary stricture during endoscopic retrograde cholangiopancreatography: a randomized trial. ENDOSCOPY, 46 (10): 857-61

6. Albert JG, Tal A, Bechstein WO, Trojan J, Schnitzbauer A (2014) Three late adverse events of choledochoduodenostomy of which the endoscopist should be aware: direct retrograde cholangioscopy is helpful for diagnosis and therapy. GASTROINTEST ENDOSC, -: -

7. Arama V, Leblebicioglu H, Simon K, Zarski JP, Niederau C, Habersetzer F, Vermehren J, Bludzin W, Jinga M, Ulusoy S, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Zeuzem S, the AI, European Longitudinal Chronic Hepatitis B Study Group (2014) Chronic hepatitis B monitoring and treatment patterns in five European countries with different access and reimbursement policies. ANTIVIR THER, -: -

8. Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JGP, Oo Y, Petersen J, van Bömmel F, de Knegt RJ, Santantonio T, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen B, Janssen HLA, for the VIRGIL Surveillance Study Group (2014) Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. GUT, -: -

9. Badenhoop K (2014) Genetics: Vitamin D and type 2 diabetes mellitus-hype or hope? NAT REV ENDOCRINOL, -: -

10. Bajer MM, Kunze MM, Blees JS, Bokesch HR, Chen H, Brauss TF, Dong Z, Gustafson KR, Biondi RM, Henrich CJ, 
McMahon JB, Colburn NH, Schmid T, Brüne B (2014) Characterization of pomiferin triacetate as a novel mTOR and 
translation inhibitor. BIOCHEM PHARMACOL, 88 (3): 313-21

11. Bergis D, Bergis PM, Hermanns N, Zink K, Haak T (2014) Coronary artery disease as an independent predictor of 
survival in patients with type 2 diabetes and Charcot neuro-osteoarthropathy. ACTA DIABETOL, 51 (6): 1041-8

12. Berg T, Andreone P, Pol S, Roberts S, Younossi Z, Diago M, Lawitz EJ, Focaccia R, Foster GR, Horban A, Lonjon- Domanec I, DeMasi R, Picchio G, Luo D, De Meyer S, Zeuzem S (2014) Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study. LIVER 
INT, -: -

13. Blumenstein I, Dignass A, Vollmer S, Klemm W, Weber-Mangal S, Stein J (2014) Current practice in the diagnosis and 
management of IBD-associated anaemia and iron deficiency in Germany: the German AnaemIBD Study. J CROHNS 
COLITIS, 8 (10): 1308-14

14. Blumenstein I, Shastri YM, Stein J (2014) Gastroenteric tube feeding: techniques, problems and solutions. WORLD J 
GASTROENTERO, 20 (26): 8505-24

15. Boursier J, de Ledinghen V, Poynard T, Guéchot J, Carrat F, Leroy V, Wong GLH, Friedrich-Rust M, Fraquelli M, 
Plebani M, Sebastiani G, Myers R, Angulo P, Bertrais S, Wendum D, Bricault I, Calès P, from the ARDENT group and/or AFEF (2014) An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. J HEPATOL, -: -

16. Brouwer WP, Sonneveld MJ, Tabak F, Simon K, Cakaloglu Y, Akarca US, Zeuzem S, Ferenci P, Heathcote JE, de Knegt RJ, Boonstra A, Hansen BE, Janssen HLA (2014) Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B. ALIMENT PHARM THER, 40 (7): 811-8

17. Bruggmann P, Berg T, Øvrehus ALH, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, Sherman M, Ryder SD, Sperl J, Akarca U, Balık I, Bihl F, Bilodeau M, Blasco AJ, Buti M, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HSM, Cornberg M, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Estes C, Falconer K, Félix J, Ferraz MLG, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL, Gower E, Gschwantler M, Guimarães Pessôa M, Hézode C, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KDE, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marotta P, Mauss S, Mendes Correa MC, Müllhaupt B, Myers RP, Negro F, Nemecek V, Örmeci N, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Rosenberg WM, Sarmento-Castro R, Sarrazin C, Semela D, Shiha GE, Sievert W, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, van Thiel I, Van Vlierberghe H, Vandijck D, Vogel W, Waked I, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Van Damme P, Aleman S, Hindman SJ (2014) Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat, 21 Suppl 1: 5-33

18. Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S, Nyberg L, Brown RS, Hezode C, Rizzetto M, Parana R, De Meyer S, De Masi R, Luo D, Bertelsen K, Witek J (2014) Telaprevir Twice Daily is Noninferior to Telaprevir Every 8 hrs for Patients with Chronic Hepatitis C. GASTROENTEROLOGY, 146 ((3)): 744-753

19. Canbay A, Feldstein A, Kronenberger B, Schulze-Osthoff K, Bantel H (2014) [Cytokeratin 18 as marker for non- invasive diagnosis and prognosis of acute and chronic liver diseases]. Z GASTROENTEROL, 52 (3): 290-5

20. Cloherty G, Cohen D, Sarrazin C, Wedemeyer H, Chevaliez S, Herman C, Bernstein B, Pawlotsky JM (2014) HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals. ANTIVIR THER, -: -

21. Dawoodji A, Chen JL, Shepherd D, Dalin F, Tarlton A, Alimohammadi M, Penna-Martinez M, Meyer G, Mitchell AL, 
Gan EH, Bratland E, Bensing S, Husebye ES, Pearce SH, Badenhoop K, Kämpe O, Cerundolo V (2014) High frequency of cytolytic 21-hydroxylase-specific CD8+ T cells in autoimmune Addison's disease patients. J IMMUNOL, 193 (5): 2118-26

22. de Boer YS, van Gerven NMF, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, Beuers U, van Buuren HR, Drenth JPH, den Ouden JW, Verdonk RC, Koek GH, Brouwer JT, Guichelaar MMJ, Vrolijk JM, Kraal G, Mulder CJJ, van Nieuwkerk CMJ, Fischer J, Berg T, Stickel F, Sarrazin C, Schramm C, Lohse AW, Weiler-Normann C, Lerch MM, Nauck M, Völzke H, Homuth G, Bloemena E, Verspaget HW, Kumar V, Zhernakova A, Wijmenga C, Franke L, Bouma G, Dutch Autoimmune Hepatitis Study Group, LifeLines Cohort Study, Study of Health in Pomerania (2014) Genome- wide association study identifies variants associated with autoimmune hepatitis type 1. GASTROENTEROLOGY, 147 (2): 443-52.e5

23. Doller A, Badawi A, Schmid T, Brauß T, Pleli T, Zu Heringdorf DM, Piiper A, Pfeilschifter J, Eberhardt W (2014) The cytoskeletal inhibitors latrunculin A and blebbistatin exert antitumorigenic properties in human hepatocellular carcinoma cells by interfering with intracellular HuR trafficking. EXP CELL RES, -: -

24. Döring G, Bragonzi A, Paroni M, Aktürk FF, Cigana C, Schmidt A, Gilpin D, Heyder S, Born T, Smaczny C, Kohlhäufl M, Wagner TOF, Loebinger MR, Bilton D, Tunney MM, Elborn JS, Pier GB, Konstan MW, Ulrich M (2014) BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. J CYST FIBROS, 13 ((2)): 156-63

25. Doerrbecker J, Friesland M, Riebesehl N, Ginkel C, Behrendt P, Brown RJP, Ciesek S, Wedemeyer H, Sarrazin C, Kaderali L, Pietschmann T, Steinmann E (2014) Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles. HEPATOLOGY, 60 (2): 508-20

26. Dultz G, Gerber L, Farnik H, Berger A, Vermehren J, Pleli T, Zeuzem S, Piiper A, Kronenberger B, Waidmann O (2014) Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus. J Viral Hepat, -: -

27. Everson G, Cooper C, Hézode C, Shiffman ML, Yoshida E, Beltran-Jaramillo T, Andreone P, Bruno S, Ferenci P, Zeuzem S, Brunda M, Le Pogam S, Nájera I, Zhou J, Navarro MT, Voulgari A, Shulman NS, Yetzer ES (2014) DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4. LIVER INT, -: -

28. Farnik H, Ferreirós N, Labocha S, Geisslinger G, Zeuzem S, Sarrazin C, Vermehren J (2014) Role of telaprevir plasma levels for predicting response to antiviral therapy in patients with hepatitis C virus genotype 1 infection. SCAND J GASTROENTERO, 49 (12): 1473-9

29. Farnik H, Weigt J, Malfertheiner P, Grützmann A, Gossner L, Friedrich-Rust M, Zeuzem S, Sarrazin C, Albert JG (2014) A multicenter study on the role of direct retrograde cholangioscopy in patients with inconclusive endoscopic retrograde cholangiography. ENDOSCOPY, 46 (1): 16-21

30. Farnik H, Zimmermann T, Herrmann E, Bechstein WO, Kronenberger B, Galle PR, Labocha S, Ferreiros N, Geisslinger G, Zeuzem S, Sarrazin C, Welker MW (2014) Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. LIVER INT, -: -

31. Fevery B, Susser S, Lenz O, Cloherty G, Perner D, Picchio G, Sarrazin C (2014) HCV RNA quantification with different assays: implications for protease-inhibitor-based response-guided therapy. ANTIVIR THER, -: -

32. Filmann N, Rey J, Schneeweiss S, Ardizzone S, Bager P, Bergamaschi G, Koutroubakis I, Lindgren S, Morena Fdl, Moum B, Vavricka SR, Schröder O, Herrmann E, Blumenstein I (2014) Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis. INFLAMM BOWEL DIS, 20 (5): 936-45

33. Finkelmeier F, Bettinger D, Köberle V, Schultheiß M, Zeuzem S, Kronenberger B, Piiper A, Waidmann O (2014) Single measurement of hemoglobin predicts outcome of HCC patients. MED ONCOL, 31 (1): 806

34. Finkelmeier F, Kronenberger B, Köberle V, Bojunga J, Zeuzem S, Trojan J, Piiper A, Waidmann O (2014) Severe 25- hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma - a prospective cohort study. ALIMENT PHARM THER, 39 (10): 1204-12

35. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M (2014) Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. GASTROENTEROLOGY, 146 (7): 1669-79.e3

36. Friedrich-Rust M, Welte M, Welte C, Albert J, Meckbach Y, Herrmann E, Kannengiesser M, Trojan J, Filmann N, Schroeter H, Zeuzem S, Bojunga J (2014) Capnographic monitoring of propofol-based sedation during colonoscopy. ENDOSCOPY, 46 (3): 236-44

37. Gane EJ, Pockros PJ, Zeuzem S, Marcellin P, Shikhman A, Bernaards C, Zhou J, Yetzer ES, Ballester R, Dwyer C, Tong X, Nájera I, Bertasso A, Hammond J, Kindrick A, Morcos PN, Smith P, Stancic S, Shulman NS (2014) Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study. LIVER INT, -: -

38. Gnirß K, Fiedler M, Krämer-Kühl A, Bolduan S, Mittler E, Becker S, Schindler M, Pöhlmann S (2014) Analysis of determinants in filovirus glycoproteins required for tetherin antagonism. VIRUSES-BASEL, 6 (4): 1654-71

39. Grammatikos G, Ferreiros N, Bon D, Schwalm S, Dietz J, Berkowski C, Fitting D, Herrmann E, Zeuzem S, Sarrazin C, Pfeilschifter J (2014) Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in HCV but not HBV infection. HEPATOLOGY, -: -

40. Grammatikos G, Jabara CB, Ahmad MQ, Herrmann E, Zeuzem S, Welsch C (2014) Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients. ANTIVIR THER, 19 (5): 455-61

41. Grammatikos G, Lange C, Susser S, Schwendy S, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Penna-Martinez M, Badenhoop K, Zeuzem S, Berg T, Sarrazin C (2014) Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients. PLoS One, 9 (2): e87974

42. Grammatikos G, Mühle C, Ferreiros N, Schroeter S, Bogdanou D, Schwalm S, Hintereder G, Kornhuber J, Zeuzem S, Sarrazin C, Pfeilschifter J (2014) Serum acid sphingomyelinase is upregulated in chronic hepatitis C infection and non alcoholic fatty liver disease. BBA-BIOENERGETICS, -: -

43. Grammatikos G, Farnik H, Bon D, Böhlig A, Bader T, Berg T, Zeuzem S, Herrmann E (2014) The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta-analysis. J Viral Hepat, 21 (8): 533-41

44. Gruber-Rouh T, Naguib NNN, Eichler K, Ackermann H, Zangos S, Trojan J, Beeres M, Harth M, Schulz B, Nour-Eldin A NE, Vogl TJ (2014) Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: Long-term results over a 10-year period. Int J Cancer, 134 (5): 1225-31

45. Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H, HIDIT-1 Study Group (2014) Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. HEPATOLOGY, 60 (1): 87-97

46. Hézode C, Brainard D, Pol S, Libert O, Symondq W, McHutchison J, Zeuzem S (2014) [In Process Citation]. MED MALADIES INFECT, 44 (6 Suppl): 1

47. Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind- Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S (2014) Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. GUT, -: -

48. Hinrichsen I, Ernst BP, Nuber F, Passmann S, Schäfer D, Steinke V, Friedrichs N, Plotz G, Zeuzem S, Brieger A (2014) Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1. Mol Cancer, 13: 11

49. Hinrichsen I, Kemp M, Peveling-Oberhag J, Passmann S, Plotz G, Zeuzem S, Brieger A (2014) Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCs. PLoS One, 9 (1): e84453

50. Husebye ES, Allolio B, Arlt W, Badenhoop K, Bensing S, Betterle C, Falorni A, Gan EH, Hulting AL, Kasperlik-Zaluska A, Kämpe O, Løvås K, Meyer G, Pearce SH (2014) Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J INTERN MED, 275 ((2)): 104-15

51. Jalan R, Pavesi M, Saliba F, Amorós A, Fernandez J, Holland-Fischer P, Sawhney R, Mookerjee R, Caraceni P, Moreau R, Gines P, Durand F, Angeli P, Alessandria C, Laleman W, Trebicka J, Samuel D, Zeuzem S, Gustot T, Gerbes AL, Wendon J, Bernardi M, Arroyo V, CANONIC Study Investigators EASL-CLIF Consortium (2014) The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute- on-chronic liver failure. J HEPATOL, -: -

52. Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, Levesque E, Durand F, Angeli P, Caraceni P, Hopf C, Alessandria C, Rodriguez E, Solis-Muñoz P, Laleman W, Trebicka J, Zeuzem S, Gustot T, Mookerjee R, Elkrief L, Soriano G, Cordoba J, Morando F, Gerbes A, Agarwal B, Samuel D, Bernardi M, Arroyo V, CANONIC study investigators of the EASL-CLIF Consortium (2014) Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J HEPATOL, 61 (5): 1038-47

53. Kaiser T, Zeuzem S, Lichtinghagen R, Welker MW, Geilenkeuser WJ, Kruse R, Neumaier M, Thiery J, Schmidt M (2014) Multi-center proficiency tests for Lab-MELD score diagnostics to improve the quality and safety for patients awaiting liver transplantation. CLIN CHEM LAB MED, 52 (12): e287-9

54. Kasama Y, Mizukami T, Kusunoki H, Peveling-Oberhag J, Nishito Y, Ozawa M, Kohara M, Mizuochi T, Tsukiyama- Kohara K (2014) B-cell-intrinsic hepatitis C virus expression leads to B-cell-lymphomagenesis and induction of NF-κB signalling. PLoS One, 9 (3): e91373

55. Kitson MT, Sarrazin C, Toniutto P, Eslick GD, Roberts SK (2014) Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: A systematic review and meta-analysis. J HEPATOL, -: -

56. König AB, Junginger S, Reusch J, Louwen F, Badenhoop K (2014) Gestational Diabetes Outcome in a Single Center Study: Higher BMI in Children After Six Months. HORM METAB RES, 46 (11): 804-9

57. Kubitz R, Dröge C, Kluge S, Stross C, Walter N, Keitel V, Häussinger D, Stindt J (2014) Autoimmune BSEP Disease: Disease Recurrence After Liver Transplantation for Progressive Familial Intrahepatic Cholestasis. CLIN REV ALLERG IMMU, -: -

58. Lange CM, Bellecave P, Dao Thi VL, Tran HTL, Penin F, Moradpour D, Gouttenoire J (2014) Determinants for membrane association of the hepatitis C virus NS2 protease domain. J VIROL, 88 (11): 6519-23

59. Lange CM, Gouttenoire J, Duong FHT, Morikawa K, Heim MH, Moradpour D (2014) Vitamin D receptor and Jak-STAT signaling crosstalk results in calcitriol-mediated increase of hepatocellular response to IFN-α. J IMMUNOL, 192 (12): 6037-44

60. Leblebicioglu H, Arama V, Causse X, Marcellin P, Ozaras R, Postawa-Klozinska B, Simon K, Suceveanu AI, Wiese M, Zeuzem S, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Zarski JP, The AI463-121 European Longitudinal Chronic Hepatitis B Study Group (2014) Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries. J Viral Hepat, -: -

61. Leung NWY, Herrmann E, Lau GKK, Chan HLY, So TMK, Zeuzem S, Dong Y, Trylesinski A, Naoumov NV (2014) Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-